Cited by 132Pain Mechanisms and TreatmentsPain Management and TreatmentMusculoskeletal pain and rehabilitation

Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study

Bouhassira, Didier, Wilhelm, Stefan, Schacht, Alexander, Perrot, Serge, Kosek, Eva, Cruccu, Giorgio, Freynhagen, Rainer, Tesfaye, Solomon +7 more·2014·Pain

Abstract

Sensory profiles are heterogeneous in neuropathic pain disorders, and subgroups of patients respond differently to treatment. To further explore this, patients in the COMBO-DN study were prospectively assessed by the Neuropathic Pain Symptom Inventory (NPSI) at baseline, after initial 8-week therapy with either duloxetine or pregabalin, and after subsequent 8-week combination/high-dose therapy. Exploratory post hoc cluster analyses were performed to identify and characterize potential subgroups through their scores in the NPSI items. In patients not responding to initial 60 mg/d duloxetine, adding 300 mg/d pregabalin for combination treatment was particularly effective regarding the dimensions pressing pain and evoked pain, whereas maximizing the duloxetine dose to 120 mg/d appeared more beneficial regarding paresthesia/dysesthesia. In contrast, adding 60 mg/d duloxetine to 300 mg/d pregabalin in case of nonresponse to initial pregabalin led to numerically higher decreases in all NPSI dimensions/items compared to maximizing the pregabalin dose to 600 mg/d. Cluster analysis revealed 3 patient clusters (defined by baseline scores for the 10 NPSI sensory items) with different pain profiles, not only in terms of overall pain severity, but also across NPSI items. Mean Brief Pain Inventory average pain improved in all clusters during combination/high-dose therapy. However, in patients with severe pain, the treatment effect showed a trend in favor of high-dose monotherapy, whereas combination therapy appeared to be more beneficial in patients with moderate and mild pain (not significant). These complementary exploratory analyses further endorse the idea that sensory phenotyping might lead to a more stratified treatment and potentially to personalized pain therapy.

Integrity signals

Registry

Crossref · 10.1016/j.pain.2014.08.020

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bouhassira, D., Wilhelm, S., Schacht, A., Perrot, S., Kosek, E., Cruccu, G., Freynhagen, R., Tesfaye, S., Lledó, A., Choy, E., Marchettini, P., Micó, J. A., Spaeth, M., Skljarevski, V., & Tölle, T.
Affiliations
  • Inserm (FR)
  • Eli Lilly (Germany) (DE)
  • Karolinska Institutet (SE)
  • Sapienza University of Rome (IT)
  • Technical University of Munich (DE)
  • Royal Hallamshire Hospital (GB)
  • Cardiff University (GB)
  • IRCCS Ospedale San Raffaele (IT)
  • Universidad de Cádiz (ES)
  • Spital Linth (CH)
  • Eli Lilly (United States) (US)
Corresponding author
Wilhelm, Stefan
Venue
Pain
Published
2014-10
Volume
155
Issue
10
Pages
2171-2179
ISSN
0304-3959 (ISSN-L)
OpenAlex
W2024753057
Cited by
132
References
28
Citations by year
2026: 5 · 2025: 6 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 16 · 2019: 13 · 2018: 14 · 2017: 10 · 2016: 14 · 2015: 11 · 2014: 2
FWCI
8.20
Type
journal article
Language
en
Open access
closed
Locations
  • Pain (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Health Sciences › Medicine › Pharmacology › Musculoskeletal pain and rehabilitation
Keywords
diabetic neuropathic pain, treatment response prediction, duloxetine, pregabalin, combination therapy, Neuropathic Pain Symptom Inventory, sensory profile, patient subgroups
MeSH terms
Duloxetine Hydrochloride, Pregabalin, Aged, Aged, 80 and over, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Severity of Illness Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review